mRNA1273 vaccine

BIOLOGICAL2 trials

Sponsors

Sheba Medical Center, Moderna Inc

Conditions

COVID-19 PandemicSARS-CoV2

Phase 3

Fourth COVID-19 Vaccine Dose- mRNA1273

Sheba Medical CenterCOVID-19 Pandemic

Start: 2022-01-05End: 2024-07-04Target: 1000Updated: 2023-12-27

Sisonke 4 (SHERPA)/ mRNA-1273-P508

Active, not recruitingPACTR202310615330649

Moderna IncSARS-CoV2

Start: 2022-04-15Target: 15000Updated: 2026-09-14

Related Papers

Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa: The single-arm, open-label, phase 3 SHERPA study

PLOS Global Public Health2024-12-052 citations

Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up.

2022-12-1322 citations